baber/WOPTO huggingface dataset:
Patent NZ-532762-A (NZ)
Title: Rapid and sensitive in vitro assay to identify genes involved in the regulation of processes involved in xylogenesis
Inventor: PUTHIGAE SATHISH
IPC: C12Q1/68
Filed: 2002-11-08
Abstract: Described is a functional assay for high-throughput screening and identification of plant genes involved in xylogenesis and secondary cell wall formation. The assay involves transforming Zinnia mesophyll cells in vitro under non-inducing or transdifferentiation-inducing conditions with DNA constructs comprising one or more polynucleotide sequences to a be tested and comparing the expression of the sequences in the non-induced and transdifferentiating cells. The assay is particularly useful for identifying promoters that are active in xylem and xylem-forming tissues and their transcriptional regulators.
Patent NZ-533566-A (NZ)
Title: Tetrahydroquinoline analogues as muscarinic agonists
Inventor: SKJAERBAEK NIELS
IPC: A61K31/55
Filed: 2002-12-23
Abstract: Disclosed herein are tetrahydroquinoline compounds of formula (I), their salts and isomers thereof, which are suitable as muscarinic receptor agonists, wherein the variables are as defined in the specification. Also disclosed is the use of these tetrahydroquinoline compounds of formula (I), pharmaceutically acceptable salts thereof, stereoisomers thereof, or a pharmaceutical composition comprising either entity, for the preparation of a medicament for the treatment of diseases or disorders associated with a cholinergic receptor or ligand thereof, wherein the diseases or disorders are selected from the group consisting of Alzheimer's disease, Parkinson's disease, schizophrenia, Huntington's chorea, Friederich's ataxia, Gilles de la Tourette's Syndrome, Down Syndrome, Pick disease, dementia, clinical depression, age-related cognitive decline, cognitive impairment, forgetfulness, confusion, memory loss, attentional deficits, deficits in visual perception, depression, pain, sleep disorders, psychosis, sudden infant death syndrome, increased intraocular pressure and glaucoma.
Patent NZ-533736-A (NZ)
Title: Compositions and methods for the diagnosis and treatment of tumor and inhibiting cell growth
Inventor: GURNEY AUSTIN L
IPC: A61P11/00
Filed: 2002-10-16
Abstract: A method for the diagnosis and treatment of a tumour in an isolated or a non-human mammal cell that expresses a specific protein. The use of such a method is also disclosed.
Patent NZ-533967-A (NZ)
Title: Methods for preserving ophthalmic solutions and preserved ophthalmic solutions
Inventor: TSAO FU-PAO
IPC: A61L12/08
Filed: 2003-01-17
Abstract: Disclosed is a method of inhibiting Cladosporium growth in an aqueous ophthalmic solution comprising a cellulose derivative and a hydrogen peroxide source, comprising: providing an aqueous solution comprising a cellulose derivative and a hydrogen peroxide source, wherein said solution will support Cladosporium growth if contaminated with Cladosporium; and admixing an effective amount of between 0.05% and 0.1% dissolved alkaline earth metal salt by weight with said solution to yield a solution which, if contaminated with Cladosporium, will allow less Cladosporium growth than an otherwise identical solution that does not comprise an alkaline earth metal salt. Further disclosed is an ophthalmic solution comprising: (a) a hydrogen peroxide source in an amount to produce trace amounts of hydrogen peroxide of less than 100 ppm (b) a cellulose derivative (c) water; and (d) an effective amount of between 0.05% and 0.1% dissolved alkaline earth metal salt by weight such that if said solution is contaminated with Cladosporium, less Cladosporium growth will occur in said solution than an otherwise identical solution that does not comprise an alkaline earth metal salt.
Patent NZ-537176-A (NZ)
Title: Apparatus to generate energy using microwave
Inventor: GUPTA RAJEEV PRASAD
Filed: 2004-12-13
Abstract: A method of converting organic material into a usable form of energy by means of microwaves comprises: a) drying the organic material to remove at least 80% to 90% of the moisture content; b) placing the dried organic material in a chamber with at least one embedded copper or tungsten ring wherein the ring has an air gap in which the dried organic material is placed; c) exposing the chamber to microwaves to induce a plasma discharge within the air gap of the ring so that the plasma discharge causes a chin reaction to occur and converts the dried o organic material into an usable form of energy. The usable form of energy can be selected from thermal, electrical, high pressure, plasma, ionized air or gas or fusion energy.
Patent NZ-543287-A (NZ)
Title: Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors
Inventor: GOBLE STEPHEN D
IPC: C07D401/00
Filed: 2004-04-08
Abstract: Disclosed are cyclopentyl compounds linked to a benzoxazinyl group through an amido moiety utilising the ring nitrogen of the benzoxazine. In particular disclosed are compounds of formula I wherein the substituents are described in the specification, useful as modulators of chemokine receptors. These compounds can be used in the treatment, amelioration, control or reduction of risk of an inflammatory and immunoregulatory disorders or diseases.
Patent NZ-543982-A (NZ)
Title: Detection of biochemical interactions on a biosensor using tunable filters and tunable lasers
Inventor: CUNNINGHAM BRIAN T
IPC: G01N33/50
Filed: 2004-05-07
Abstract: An apparatus and method for detection of peak wavelength values of colorimetric resonant optical biosensors using tunable filters and tunable lasers is disclosed. Biomolecular interactions may be detected on a biosensor by directing collimated white light towards a surface of the biosensor. Molecular binding on the surface of the biosensor is indicated by a shift in the peak wavelength value of reflected or transmitted light from the biosensor, while an increase in the wavelength corresponds to an increase in molecular absorption. A tunable laser light source may generate the collimated white light and a tunable filter may receive the reflected or transmitted light and pass the light to a photodiode sensor. The photodiode sensor then quantifies an amount of the light reflected or transmitted through the tunable filter as a function of the tuning voltage of the tunable filter.
Patent NZ-547666-A (NZ)
Title: Display stand
Inventor: JACKSON PETER LINDSAY
Filed: 2006-06-06
Abstract: A display stand for the display of greeting cards simultaneously with other items. The display stand includes a greeting card display rack having a plurality of card display tiers, each tier including means for displaying at least one greeting card. A storage and display compartment is provided for containing the other items, the compartment having a permanent opening located below the greeting card display rack whereby, when items are contained therein, at least one of said items is visible and accessible via said opening. In preferred embodiments, the other items are roll wrap products. The display stand enables the more efficient and effective use of storage and display space within a retail environment.
Patent NZ-548178-A (NZ)
Title: Topical formulations comprising a 1-N-arylpyrazole derivative and a formamidine
Inventor: BOECKH ALBERT
IPC: A01N47/02
Filed: 2004-12-17
Abstract: Disclosed is a topical formulation comprising an effective amount of an ectoparasitical combination comprising an 1-N-arylpyrazole derivative such as fipronil and a formamidine such as amitraz, a pharmaceutical or veterinary acceptable liquid carrier vehicle, and optionally, a crystallization inhibitor.
Patent NZ-549457-A (NZ)
Title: Watchdog system and method for monitoring functionality of a processor
Inventor: PRAGASH VEDAM JUDE
IPC: G06F11/00
Filed: 2005-01-28
Abstract: A watchdog system for monitoring functionality of a processor is disclosed. The system comprises control logic having N number of acknowledgement signal inputs. The system also comprises a first timer, a second timer; a third timer, and a reset signal generator. The first timer is started upon boot up of the watchdog system. The second and third timers are started upon receiving a first acknowledgement signal at one of said N number of acknowledgement signal inputs. The reset signal generator generates a reset signal if any one of three conditions is met. The first condition is that no acknowledgement signal was received at one of the N number of acknowledgement signal inputs before the expiration of the first timer. The second condition is that an acknowledgement signal is received at one of the N number of acknowledgement signal inputs before the expiration of the second timer. The third condition is that an acknowledgement signal was not received at all the N number of acknowledgement signal inputs before the expiration of the third timer.
Patent NZ-550946-A (NZ)
Title: A teatcup liner and a teatcup
Inventor: KASSIBRAHIM JAN
IPC: A01J/
Filed: 2005-05-19
Abstract: Disclosed is a teatcup liner (1) which is mounted in a shell (2) of the teatcup and defines an inner space (3) for receiving a teat. The liner includes a primary component (11) which forms an upper head of the teatcup. The primary component includes a primary peripheral portion (15), a primary connecting ring (16) and a lip (17) defining an opening (4) for the introduction of the teat. The liner further includes a secondary component (12) which forms a barrel of the teatcup. The secondary component includes a secondary peripheral portion (18) and a secondary connecting ring (20). The primary component is connectable to the secondary component which realises the liner by a mutual engagement of the connecting rings. The connecting ring of at least one of the components abuts the peripheral portion of the other component to form a sealing abutment between the primary component and the secondary component.
Patent NZ-553982-A (NZ)
Title: pH Stabilized leukotriene B4 (LTB4) agent pharmaceutical formulation
Inventor: BORGEAT PIERRE
IPC: C07C33/02
Filed: 2005-09-20
Abstract: Disclosed is a stabilized LTB4 agent pharmaceutical formulation, comprising a therapeutically effective amount of an LTB4 agent, a salt thereof, an ester thereof, or an ether thereof in association with a pharmaceutically acceptable carrier at an alkaline pH between 8.2 and 14 effective to stabilize said LTB4 agent, thereby increasing said formulation shelf-life, or a pharmaceutically acceptable, alkaline reacting carrier; wherein the LTB4 agent is one or more of the polyunsaturated fatty acids selected from the group consisting of LTB4, 14,15-dihydro-LTB4, 17,18-dehydro-LTB4, 19-hydroxy-LTB4, 20-hydroxy-LTB4 and their 5(R)-hydroxy, 5(S)-hydroperoxy, 5(R)-hydroperoxy and 5-deoxy analogs; LTA4; 14,15-dihydro-LTA4, 17,18-dehydro-LTA4; 14,15-dihydro-LTA4 methyl ester, LTA4 methyl ester, 5(S)-hydroxy-6,8,11,14(E,Z,Z,Z)-eicosatetraenoic acid ("5-HETE"), 14,15-dihydro-5-HETE, 17,18-dehydro-5-HETE, and their 5(R)-hydroxy, 5(S)-hydroperoxy, 5(R)-hydroperoxy analogs, and wherein an alkaline reacting carrier is an otherwise inert, pharmaceutically acceptable substance (or substances), which creates an alkaline micro-pH between 8.2 and 14 around each LTB4 particle, in the case of the stabilised LTB4 formulation being in a freeze-dried, crystalline, or solid amorphous form, when water is adsorbed to the particles of the mixture or when water is added in small amounts to the mixture. Suitable carriers include aqueous carriers (selected from the group consisting of water, alkaline metal hydroxide solutions (such as sodium hydroxide solution), buffered saline solutions (such as phosphate buffered saline (PBS)), alcohol-containing aqueous solution, sugar solutions, or a mixture thereof), and carriers which are a particulate solid coated with an alkaline matrix or constituted of an alkaline matrix. The above composition may also further comprise a chelating agent (such as aminopolycarboxylic acid, ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTPA), nitrilotriacetic acid (NTA), glutamic acid, and aspartic acid) or a pharmaceutically acceptable salt of a chelating agent thereof in an amount effective to stabilize said LTB4 agent.
Patent NZ-553993-A (NZ)
Title: Assigning and deallocation of random access memory for user program
Inventor: MCNAMEE JOHN CHRISTOPHER
Filed: 2000-05-11
Abstract: A telecommunications system includes a means to establish a connection with an external user interface device through a telecommunications link, and a random access memory. A portion of the random access memory can be allocated to a user, and a software application for carrying out a user requested process is loaded into the portion of the random access memory allocated to the user. A viewable or audible representation of the process is conveyed to the user and commands from the user for the process are conveyed through the connection. If the user connection is terminated or the process operating from the software loaded into the allocated random access memory is concluded, the allocated portion of the random access memory is re-allocated to a different user.
Patent NZ-571773-A (NZ)
Title: 2-Methylene-1alpha,25-dihydroxy-18,19,21-trinorvitamin D3 and uses thereof
Inventor: DELUCA HECTOR F
IPC: A61P19/08
Filed: 2007-04-06
Abstract: Disclosed are 2-methylene-1a,25-dihydroxy-18,19,21-trinorvitamin D3 compounds as represented by the general formula I, wherein X1, X2 and X3 are independently selected from H and hydroxy protecting groups. Further disclosed is a pharmaceutical composition which comprises an effective amount of a compound as defined above for the treatment of a biological condition selected from metabolic bone disease; psoriasis; leukemia; colon cancer; breast cancer; prostate cancer; skin cancer; lung cancer; multiple sclerosis; lupus; diabetes mellitus; host versus graft reaction; rejection of organ transplants; an inflammatory disease selected from rheumatoid arthritis, psoriatic arthritis, asthma, or inflammatory bowel diseases; a skin condition selected from wrinkles, lack of adequate skin firmness, lack of adequate dermal hydration, or insufficient sebum secretion; osteopenia; renal osteodystrophy; vitamin D-resistant rickets; or osteoporosis.
Patent NZ-573820-A (NZ)
Title: Wound dressing having voids that are large and resistant to collapse for encouraging cellular growth
Inventor: KARPOWICZ JOHN
IPC: A61F13/00
Filed: 2007-07-06
Abstract: A wound contact device (300) for use in treating a wound is disclosed. The device (300) facilitates wound healing with suction- assisted wound therapy to encourage cellular activity. The device (300) comprises a permeable material and a wound contact layer having voids. The voids (304) extend through the wound contact layer into the permeable material. The wound contact layer can comprise a thin sheet or film forming a generally flat and smooth wound contact surface (310) having essentially no discontinuities or gaps. In progressive wound healing, an embodiment of the wound contact device (300) having the fabric contact surface is used in earlier healing stages and an embodiment of the wound contact device (300) with film contact surface is used in later healing stages.
Patent NZ-575901-A (NZ)
Title: Alphavirus replicon particles matched to protein antigens as immunological adjuvants
Inventor: SMITH JONATHAN F
IPC: C12N15/86
Filed: 2007-09-12
Abstract: Disclosed is the use of an immunogenic protein and alphavirus replicon particles expressing said immunogenic protein in the manufacture of one medicament or separate medicaments to be administered to a subject for enhancing the immune response to the immunogenic protein in said subject, wherein the particles and the immunogenic protein are to be administered simultaneously and at the same location.
Patent NZ-580454-A (NZ)
Title: Amino- pyridine derivatives as s1p1 /edg1 receptor agonists
Inventor: BOLLI MARTIN
IPC: A61K31/4439
Filed: 2008-02-29
Abstract: Disclosed is a compound of formula (I), wherein A is defined as shown and the remaining substituents are as defined in the specification. The compounds are S1P1/EDG1 receptor agonists useful for improving vascular function and as immunomodulating agents.
Patent NZ-584342-A (NZ)
Title: Improved door closing mechanism and cabinet including the same
Inventor: URQUHART DAVID
IPC: E05G1/026
Filed: 2010-03-30
Abstract: Disclosed is a door closing mechanism for a cabinet. The door closing mechanism includes primary door with a first door lug and a slave door with a second door lug. The mechanism further includes a rocker arm moveable between a first position in which the rocker arm prevents the slave door from closing and a second position in which the slave door is free to close. The rocker arm is biased towards the first position. The second door lug is configured to maintain the rocker arm in the first position and thereby prevent closure of the slave door until the first door lug moves the rocker arm towards its second position. The first door lug is configured so that this movement occurs upon closure of the primary door.
Patent NZ-586081-A (NZ)
Title: An adjustable brace band for securing a portable electronics device in a hands free manner
Inventor: MORI KENNETH
IPC: A45F3/14
Filed: 2008-11-17
Abstract: An apparatus to carry a portable device, the apparatus comprising: a brace body; an adjustment mechanism coupled to the brace body and configured to adjust the apparatus for an adjusted fit and retain the adjusted fit for the apparatus when not in use; and a locking mechanism coupled to the brace body and configured to conform to a locked state to configure the apparatus for a bracing fit; and conform to an unlocked state to configure the apparatus for a relaxed fit. The bracing fit is configured to brace the apparatus to a usage position of a user. The relaxed fit permits positioning of the apparatus relative to the usage position. The brace body comprises a brace band comprising a first portion routed from the locking mechanism to the adjustment mechanism, a second portion coupled to the first portion and routed from the adjustment mechanism back to the locking mechanism and a third portion coupled to the second portion and routed from the locking mechanism back to the adjustment mechanism. The first and second portions are contiguous relative to each other along the brace band and the second and third portions are contiguous relative to each other along the brace band.
Patent NZ-596678-A (NZ)
Title: Plant harvesting/packaging machine comprising a device for uniformly distributing plants returned to the ground
Inventor: WATTRON BERNARD
IPC: A01D43/10
Filed: 2010-07-05
Abstract: 596678 Disclosed is a harvesting/packaging machine to evenly distribute waste plant matter back to the ground after harvesting. The mower conditioner machine includes a harvesting mechanism provided with a cutter (3), a plant-packaging system (4), and a means for collecting the elements from the ground, the assembly being supported by a frame (1) provided with a shroud or fairing(13), the machine, also comprising a plant ejection tunnel (14) uninterruptedly arranged with the packaging system (4), is characterized in that the shroud (13) is hinged to the ejection tunnel (14) by means of a transverse pin (17) positioned in the machine above and slightly behind the plant-packaging system (4), and in that the ejection tunnel (14) is in turn hinged to the frame (1).
Patent NZ-599402-A (NZ)
Title: 2’ -fluoro substituted carba-nucleoside analogs for antiviral treatment
Inventor: CHO AESOP
IPC: C07D487/04
Filed: 2010-09-20
Abstract: ABSTRACT - 599402 The disclosure relates to pyrrolo[1,2-f][1,2,4]triazinyl, imidazo[1,5-f][1,2,4]triazinyl, imidazo(1,2-f][1,2,4]triazinyl, and [1,2,4]triazolo[4,3-f][1,2,4]triazinyl nucleosides of Formula I or an acceptable salt, thereof wherein the variables are defined in the specification, wherein the 2’ position of the nucleoside sugar is substituted with halogen and carbon substituents. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections caused by both wild type and mutant strains of HCV.
Patent NZ-599536-A (NZ)
Title: Variable path length probe
Inventor: BORN CHRISTIAN
IPC: G01N21/85
Filed: 2009-12-10
Abstract: A probe is provided having a probe head (2) in which is formed an opening (10) for receiving a sample to be analysed. The head (2) comprises a pair of optical interfaces (16; 18), each disposed at a respective opposing inner surface of the opening (10) to delimit a path (26) for optical radiation through the opening (10). At least one of the pair of optical interfaces (18) comprises an element (32) transparent to the optical radiation in the wavelength region(s) of interest and is disposed to permit the optical radiation to travel between internal (28) the probe head and the opening (10). The probe further comprises a movable diaphragm (24) in which a one (18) of the pair of optical interfaces (16; 18) is located for movement therewith and an actuator (46) is located within the probe head (2) and in operable connection to the diaphragm (24) to control its movement so as to vary the path length of the path (26) for optical radiation.
Patent NZ-600479-A (NZ)
Title: New co-crystals of agomelatine, a process for their preparation and pharmaceutical compositions containing them
Inventor: LETELLIER PHILIPPE
IPC: A61K31/16
Filed: 2012-06-06
Abstract: ABSTRACT - 600479 The disclosure relates to a co-crystal of agomelatine, characterised in that it is composed of: (i) agomelatine, or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide of formula (I), and (ii) an organic acid which is in a solid state at ambient temperature chosen from parahydroxybenzoic acid, citric acid, oxalic acid, gallic acid, maleic acid, malonic acid, glutaric acid, glycolic acid or ketoglutaric acid. Also disclosed is a process for obtaining said co-crystal comprising the following steps wherein: (i) the two constituents are mixed in an organic solvent in the desired proportions (1 equivalent of agomelatine per 0.25 to 4 molar equivalents of organic acid), preferably the two constituents are co-ground; (ii) the solution obtained is stirred and optionally heated at a temperature not greater than the boiling point of the selected solvent; (iii) the mixture is cooled, with stirring, and the co-crystal precipitates naturally or precipitates after taking up in a second solvent; (iv) the precipitate obtained is filtered and dried. These co-crystals are suitable for treating stress, sleep disorders, anxiety disorders and especially generalised anxiety disorder, obsessive-compulsive disorders, mood disorders and especially bipolar disorders, major depression, seasonal affective disorder, cardiovascular pathologies, pathologies of the digestive system, insomnia and fatigue due to jet-lag, schizophrenia, panic attacks, melancholia, appetite disorders, obesity, insomnia, pain, psychotic disorders, epilepsy, diabetes, Parkinson's disease, senile dementia, various disorders associated with normal or pathological ageing, migraine, memory loss, Alzheimer's disease, and also in cerebral circulation disorders, and also in sexual dysfunctions, and as ovulation inhibitors and immunomodulators and in the treatment of cancers.